Tang Y, et al. - Whether current maintenance treatments including different regimens of long-acting β2-agonists (LABA) with inhaled corticosteroids (ICS) are safe as well as efficacious for patients with asthma, was investigated in this network meta-analysis. Researchers explored PubMed, Cochrane Library, and Embase databases up to January 1, 2017, to identify randomized clinical trials comparing LABA combined with ICS in asthma cases. They analyzed a total of 17 trials involving 10,961 patients and seven treatment regimens. According to the findings, the different regimens of LABA + ICS had no statistically significant differences in terms of frequency of moderate or severe exacerbations, adverse events, and symptom-free days.